The Development of and Off-the-Shelf CAR T-Cell Therapy Targeting CD19 and CD38 for Broad Application in Autoimmune Disease
Targeting of Tumor Antigen CD38 and Stress Antigens MICA/B by CAR T-Cells Provides a Unique Approach for the Comprehensive Treatment of Multiple Myeloma
Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-derived CAR T-cell Therapy
iPSC-Derived, Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Next-Generation Off-the-Shelf CAR T-Cells: A Novel Platform to Enable Comprehensive Elimination of Aberrant Effector Cells for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
Next Generation CAR-NK cell Therapy Leverages Alloimmune Defense Technology to Persist Without Conditioning Chemotherapy for the Treatment of Autoimmune Disease
Treatment of Refractory SLE with Off-the-Shelf iPSC-derived Anti-CD19 CAR T-cell Therapy
FT836, a Novel MICA/B-targeting CAR T-cell Therapy Engineered to Eliminate the Need for Conditioning Chemotherapy with Broad Activity Across Solid Tumor Indications
Targeting uPAR with Multiplexed-Engineered iPSC-Derived CAR T Cells to Reverse Age- and Insult-Related Fibrotic Disease
Next-Generation Off-the-Shelf CAR T-Cell Therapies for Conditioning-Free Treatment of a Broad Spectrum of In collaboration with Autoimmune Diseases and Hematologic Malignancies
Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy
Phase 1 Translational Assessment of an Off-The-Shelf CAR NK Cell Armed with Alloimmune Defense Technology for Conditioning-free Therapy
FT522: A CAR NK Cell with the Unique Ability to Target Multiple Pathogenic Cell Types and Circumvent Lympho-conditioning in Systemic Autoimmunity
FT819-102: Clinical Translation of Off-the-Shelf TCR-less CD8αβ+ anti-CD19 CAR-T Cells for The Treatment of B cell-mediated Autoimmune Disorders
2024 ASGCT Poster Presentation
A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors
High-Density Cryopreservation of Off-the-Shelf CAR Cells Facilitates On-demand Treatment Access
Alloimmune Defense Receptor Redirects Host Immune Cell Alloreactivity to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf Cell-Based Cancer Therapy
A CD3 Fusion Receptor (CD3-FR) Uniquely Enables Compatibility of Allogeneic CAR-T and -NK cells with T Cell Engagers to Enhance Antitumor Function and Limit Antigen Escape
Off-the-Shelf CAR-NK cell Therapy co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma
CD82 Is Sufficient to Uniquely Identify Pluripotent Stem Cell-Derived Hemogenic Endothelium With the Hematopoietic Lineage Potency to Give Rise To Bona Fide Lymphocytes
iPSC-derived CD38-null NK Cells in Combination with CD38-targeted Antibody: a Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma
Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection
Characterization of Engineered Macrophages and other Myeloid Cells Differentiated from CD34+ Hematopoietic Progenitor Cells Derived from Pluripotent Stem Cells
Interim Phase I Clinical Data of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myelomoa
2022 ASH Poster Presentation
Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
2022 ASH Poster Presentation
A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogeneous Population Associated with AML
2022 ASH Poster Presentation
Multi-Antigen Targeting by Novel Combination of CAR-T Cells and hnCD16 Transgene Yields in Complete Tumor Clearance via Antibody Dependent Cellular Cytotoxicity
2022 ASH Poster Presentation
The Development of Allogeneic Tips-Derived TCR- CAR+ CD8⍺β T Cells
Novel Immune Reconstitution Model Highlights the Importance of Stealth Strategies that Potentiate Effector Cell Function and Promote Functional Persistence of Next-Generation Adoptive Cell Therapies
2022 SITC Poster Presentation
Trimodal CAR+TCR+hnCD16+ iPSC-derived T Cells Co-Targeting Surface and Intracellular/Neoantigens Demonstrate Additive Effect on Overcoming Tumor Heterogeneity and Cancer Escape
2022 SITC Poster Presentation
iPSC-derived NK cells Engineered with a Novel TGFβ signal Redirector Receptor Exhibit Enhanced Performance Against Solid Tumors
2022 SITC Poster Presentation
Preclinical in vivo Model Development: Highlighting Success and Discussing Xenograft Advancements, a Step Closer in Predicting Patient Outcomes
2022 SITC Poster Presentation
Engineering of Synthetic Chemokine Receptors into iPSC-derived CAR-T cells to Increase Homing and Enhance Trafficking into Solid Tumors
2022 SITC Poster Presentation
Off-the-Shelf iPSC-derived CAR-T cells Containing Seven Functional Edits Overcome Antigen Heterogeneity, Improve Trafficking, and Withstand Immunosuppression Associated with Failed Tumor Treatment
2022 SITC Poster Presentation
Off-the-Shelf iPSC-derived CAR-T cells Targeting KLK2 Demonstrate Prolonged Tumor Control and Survival in Xenograft Models of Prostate Cancer
2022 SITC Poster Presentation
Long-term Stability Assessment of Cryopreserved iPSC-derived T and NK Cells Supports Mass Production and Off-the-shelf Therapeutic Applications
2022 ASGCT Posters
Long-term Stability of iPSC-Derived CD34+ Cell Banks Supports the Sustainable Manufacture of Off-the-shelf Immunotherapies
2022 ASGCT Posters
Development of Next-Generation, Off-the-Shelf CAR T-cell Immunotherapies for Solid Tumors
2022 ASGCT Posters
Development of Master Multiplexed-Engineered iPSC Bank for Off-the-Shelf Cell-Based Cancer Immunotherapy with Reduced Conditioning Chemotherapy
2022 ASGCT Posters
10-year Stability Assessment of Cryopreserved, Engineered iPSC Banks: Genetic and Phenotypic Characterization
2022 ASGCT Posters
Robust T-cell Cellular Reprogramming and Single-cell Engineering Platform Overcomes Inconsistencies and Heterogeneity Associated with Engineering Primary T cells
2022 ASGCT Posters
iPSC-derived CD38-null NK cells in Combination with CD38-targeted Antibody Represent a Novel Therapeutic Strategy to Reduce the Requirement of Conditioning Chemotherapy for Off-the-Shelf Cell-based Cancer Immunotherapy
2022 ASGCT Posters
A novel synthetic stealth receptor that redirects host immune cell alloreactivity and potentiates functional persistence of adoptively transferred off-the-shelf cell-based cancer therapy
2022 AACR Posters
Chimeric CD3 Fusion Receptors Expressed on iPSC-derived Universal TCR-less CAR-T and -NK Cells Synergize with Bispecific Engagers to Enhance Antitumor Activity and Limit Antigen Escape
2022 AACR Posters
Novel Combination of iPSC-derived Dual Dual -CAR NK Cells with CD16 Fc Receptor for Multi-antigen Targeting of Multiple Myeloma to Overcome Clonal Resistance and Antigen Escape
2022 AACR Posters
Multiplexed-engineered, iPSC-derived T Cells Expressing Three Unique Targeting Modalities Address Tumor Heterogeneity and Antigen Escape
2022 AACR Posters
Detection of Genetically Engineered iPSC-derived Natural Killer Cells in Blood and Tissue
2022 AACR Posters
Synthetic redirection of TGFβ receptors as a novel strategy to enhance the anti-tumor activity of CAR-T cells in solid tumors
2021 SITC Abstract
Novel FcyR recombinant fusion facilitates antibody arming of engineered iPSC-derived NK cells to enhance targeting and killing of ovarian cancer cells
2021 SITC Abstract
Chemokine receptor engineering enhances trafficking and homing of primary and iPSC-derived CAR-T cells to solid tumors
2021 SITC Abstract
Dual Chimeric Antigen Receptor Approach Combining Novel Tumor Targeting Strategies Circumvents Antigen Escape in Multiple Myeloma
2021 ASH Abstract
Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection
2021 ASH Abstract
Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape
2021 ASH Abstract
Arming of iPSC-Derived NK Cells Expressing a Novel CD64 Fusion Receptor with Therapeutic Antibodies Represents a Novel Off-the-Shelf, Antigen-Targeting Strategy for Cancer
2021 ASH Abstract
Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy
2021 ASH Abstract
FT576: Multi specific Off the Shelf CAR NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self Fratricide and Optimized mAb Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma
2020 ASH Poster Presentation